Abstract
We conducted a prospectively randomized clinical trial to compare the efficacy and safety of subcutaneous interferon-α2a, subcutaneous interleukin-2 and intravenous 5-fluorouracil as home therapy against oral tamoxifen in 78 patients with progressive metastatic renal cell carcinoma. Treatment courses consisted of interferon-α2a 5 × 106 IU m–2day 1 weeks 1 + 4; days 1, 3, 5 weeks 2 + 3; 10 × 106 IU m–2days 1, 3, 5 weeks 5–8; interleukin-2 10 × 106 IU m–2twice daily days 3–5 weeks 1 + 4; 5 × 106 IU m–2days 1, 3, 5 weeks 2 + 3; and 5-fluorouracil 1000 mg m–2day 1 weeks 5–8. The tamoxifen group received tamoxifen 80 mg twice daily over 8 weeks. Among 41 patients treated with interleukin-2, interferon-α2a and 5-fluorouracil there were 7 complete (17.1%) and 9 partial responders (21.9%), with an overall objective response rate of 39.1% (95% CI, 24.2–55.5). An additional 15 patients (36.6%) were stable throughout therapy. The overall survival was 24 months (range 5–76+). In 37 patients receiving tamoxifen no objective remissions occurred. 13 patients (35.1%) had stable disease and 24 patients (64.9%) showed continued disease progression. The overall survival was 13 months (range 3–73+). In summary, this home-based therapy regimen of interferon-α2a, interleukin-2 and 5-fluorouracil demonstrated significant therapeutic efficacy in patients with progressive renal cell carcinoma when compared to hormonal therapy. © 2001 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Atzpodien J, Korfer A, Franks CR, Knuver-Hopf J, Lopez-Hanninen E, Fischer M, Mohr H, Dallmann I and Hadam M (1990) Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies. Lancet 335: 1509–1512
Atzpodien J, Poliwoda H and Kirchner H (1991) alpha-Interferon and interleukin-2 in renal cell carcinoma: studies in nonhospitalized patients. Semin Oncol 18: 108–112
Atzpodien J, Lopez HE, Kirchner H, Bodenstein H, Pfreundschuh M, Rebmann U, Metzner B, Illiger HJ, Jakse G and Niesel T (1995) Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma. J Clin Oncol 13: 497–501
Dutcher JP, Atkins M, Fisher R, Weiss G, Margolin K, Aronson F, Sosman J, Lotze M, Gordon M, Logan T and Mier J (1997) Interleukin-2-based therapy for metastatic renal cell cancer: the Cytokine Working Group experience, 1989–1997. Cancer J Sci Am 3: S73–S78
Early Breast Cancer Trialists’ Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339: 1–15
Ellerhorst JA, Sella A, Amato RJ, Tu SM, Millikan RE, Finn LD, Banks M and Logothetis CJ (1997) Phase II trial of 5-fluorouracil, interferon-alpha and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma. Cancer 80: 2128–2132
Elson PJ, Witte RS and Trump DL (1988) Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res 48: 7310–7313
Figlin RA, Belldegrun A, Moldawer N, Zeffren J and deKernion J (1992) Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2A: an active outpatient regimen in metastatic renal cell carcinoma [see comments]. J Clin Oncol 10: 414–421
Hofmockel G, Langer W, Theiss M, Gruss A and Frohmuller HG (1996) chemo-immunotherapy for metastatic renal cell carcinoma using a regimen of interleukin-2, interferon-alpha and 5-fluorouracil [see comments]. J Urol 156: 18–21
Joffe JK, Banks RE, Forbes MA, Gruss A and Frohmuller HG (1996) A phase II study of interferon-alpha, interleukin-2 and 5-fluorouracil in advanced renal carcinoma: clinical data and laboratory evidence of protease activation. Br J Urol 77: 638–649
Krown SE (1985) Therapeutic options in renal-cell carcinoma. Semin Oncol 12: 13–17
Lee RE, Lotze MT, Skibber JM, Tucker E, Bonow RO, Ognibene FP, Carrasquillo JA, Shelhamer JH, Parrillo JE and Rosenberg SA (1989) Cardiorespiratory effects of immunotherapy with interleukin-2. J Clin Oncol 7: 7–20
Lopez-Hanninen E, Kirchner H and Atzpodien J (1996) Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J Urol 155: 19–25
Maldazys JD and deKernion JB (1986) Prognostic factors in metastatic renal carcinoma. J Urol 136: 376–379
Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, Ravaud A, Mercatelllo A, Peny J, Mousseau M, Philip T and Tursz T (1998) Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d’Immunotherapie [see comments]. N Engl J Med 338: 1272–1278
Patel NP and Lavengood RW (1978) Renal cell carcinoma: natural history and results of treatment. J Urol 119: 722–726
Reiter Z, Ozes ON, Blatt LM and Taylor MW (1992) A dual anti-tumor effect of a combination of interferon-alpha or interleukin-2 and 5-fluorouracil on natural killer (NK) cell-mediated cytotoxicity. Clin Immunol Immunopathol 62: 103–111
Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Marston Linehan W, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG and White DE (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316: 889–897
Rosenstein M, Ettinghausen SE and Rosenberg SA (1986) Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J Immunol 137: 1735–1742
Schomburg A, Kirchner H, Fenner M, Menzel T, Poliwoda H and Atzpodien J (1993) Lack of therapeutic efficacy of tamoxifen in advanced renal cell carcinoma. Eur J Cancer 29A: 737–740
Sella A, Kilbourn RG, Gray I, Finn L, Zukiwski AA, Ellerhorst J, Amato RJ and Logothetis CJ (1994) Phase I study of interleukin-2 combined with interferon-alpha and 5-fluorouracil in patients with metastatic renal cell cancer. Cancer Biother 9: 103–111
Sleijfer DT, Janssen RA, Buter de Vries EG, Willemse PH and Mulder NH (1992) Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis. J Clin Oncol 10: 1119–1123
Stahl M, Wilke HJ, Seeber S and Schmoll HJ (1992) Cytokines and cytotoxic agents in renal cell carcinoma: a review. Semin Oncol 19: 70–79
Tourani JM, Pfister C, Berdah JF, Benhammouda A, Salze P, Monnier A, Paule B, Guillet P, Chretien Y, Brewer Y, Di Palma M, Untereiner M, Malaurie E, Tadrist Z, Pavolitch JM, Hauteville D, Mejean A, Azagury M, Mayeur D, Lucas V, Krakowski I, Larregain-Fournier D, Abourachid H, Andrieu JMN and Chastang C (1998) Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with flurouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized phase II study. Subcutaneous Administration Propeukin Program Cooperative Group. J Clin Oncol 16: 2505–2513
van Herpen CM, Jansen RL, Kruit WH, Hoekman K, Groenewegen G, Osanto S and de Mulder PH (2000) Chemoimmunotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party. Br J Cancer 82: 772–776
Wadler S and Schwartz EL (1990) Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res 50: 3473–3486
West WH, Tauer KW, Yannelli JR, Marshall GD, Orr DW, Thurman GB and Oldham RK (1987) Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 316: 898–905
Wirth M (1991) The current use of interferons, interleukin-2 and tumor necrosis factor in renal cell cancer. Urol Int 47: 219–230
Author information
Authors and Affiliations
Consortia
Additional information
The first author is supported by grants of Deutsche Krebshilfe, Wilhelm-Sander-Stiftung and Gesellschaft zur Förderung immunologischer Krebstherapien e.V.
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Atzpodien, J., Kirchner, H., Illiger, H. et al. IL-2 in combination with IFN-αand 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. Br J Cancer 85, 1130–1136 (2001). https://doi.org/10.1054/bjoc.2001.2076
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2001.2076
Keywords
This article is cited by
-
Adjuvant therapy for renal cell carcinoma in 2023: hopes and disappointments
World Journal of Urology (2023)
-
Harnessing cancer immunotherapy during the unexploited immediate perioperative period
Nature Reviews Clinical Oncology (2020)
-
Association between treatment effects on disease progression end points and overall survival in clinical studies of patients with metastatic renal cell carcinoma
British Journal of Cancer (2012)